Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro–in vivo evaluations

References

• Ling SS, Magosso E, Khan NA, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 2006;32:335–45
   PubMed Web of Science ®Google Scholar
• Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3–16
   PubMed Web of Science ®Google Scholar
• Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3–19
   PubMed Web of Science ®Google Scholar
• Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci 2015;10:13–23
   Web of Science ®Google Scholar
• Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008;3:295–309
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004;56:827–40
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631–44
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113–20
   PubMed Web of Science ®Google Scholar
• Juhnke M, Martin D, John E. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur J Pharm Biopharm 2012;81:214–22
   PubMed Web of Science ®Google Scholar
• Jain S, Jain S, Mishra A, et al. Formulation and characterization of fast disintegrating tablets containing Cefdinir solid dispersion. Int J Of Pharm & Life Sci 2012;3:2190–9
   Google Scholar
• Garrepally P, Rao GC. Design, development and evaluation of stomach specific in situ gel for antibiotics: Cefdinir. Int J Pharm Bio Sci 2014;4:128–37
   Google Scholar
• Thota S, Syed MA, Bomma R, Veerabrahma K. Development and in vivo evaluation of cefdinir nanosuspension for improved oral bioavailability. Int J Pharm Sci Nanotechnol 2014;7:2553–60
   Google Scholar
• Yadollahi R, Vasilev K, Simovic S. Nanosuspension technologies for delivery of poorly soluble drugs. J Nanomater 2015;2015:1–13
   Web of Science ®Google Scholar
• Patel Y, Poddar A, Sawant KK. Improved oral bioavailability of cefuroxime axetil utilizing nanosuspensions developed by media milling technique. Pharm Nanotechnol 2014;2:1–12
   Google Scholar
• Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008;364:64–75
   PubMed Web of Science ®Google Scholar
• Yadollahi R, Vasilev K, Prestidge CA, Simovic S. Polymeric nanosuspensions for enhanced dissolution of water insoluble drugs. J Nanomater 2013;2013:1–10
   Web of Science ®Google Scholar
• Singh B, Bhatowa R, Tripathi CB, Kapil R. Developing micro-/nanoparticulate drug delivery systems using “design of experiments”. Int J Pharm Investig 2011;1:75–87
   PubMedGoogle Scholar
• Turk CT, Oz U, Serim TM, Hascicek C. Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments. AAPS PharmSciTech 2014;15:161–76
   PubMed Web of Science ®Google Scholar
• Thakkar HP, Patel BV, Thakkar SP. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci 2011;3:426–34
   PubMedGoogle Scholar
• Wallace SJ, Li J, Nation RL, Boyd BJ. Drug release from nanomedicines: selection of appropriate encapsulation and release methodology. Drug Deliv Transl Res 2012;2:284–92
   PubMed Web of Science ®Google Scholar
• Thakar K, Joshi G, Sawant KK. Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies. Drug Dev Ind Pharm 2013;39:880–8
   PubMed Web of Science ®Google Scholar
• Bhalekar MR, Upadhaya PG, Reddy S, et al. Formulation and evaluation of acyclovir nanosuspension for enhancement of oral bioavailability. Asian J Pharm 2014;8:110–18
   Google Scholar
• Khan A, Iqbal Z, Khan MI, et al. Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: method development, optimization, validation, and its application to a pharmacokinetic study. J Chromatogr B 2011;879:2423–9
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Mitra A. Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds. AAPS J 2012;14:677–87
   PubMed Web of Science ®Google Scholar
• Singh VK, Chandra D, Singh P, et al. Nanosuspension: way to enhance the bioavailability of poorly soluble drug. Int J Curr Trends Pharm Res 2013;1:277–87
   Google Scholar
• Jorwekar P, Phatak AA, Chaudhri PD. Formulation development of aceclofenac loaded nanosuspension by three square (32) factorial design. Int J Pharm Sci Nanotechnol 2012;4:1575–82
   Google Scholar
• Mothilal M, Chaitanya Krishna M, Surya Teja SP, et al. Formulation and evaluation of naproxen-Eudragit® RS 100 nanosuspension using 32 factorial design. Int J Pharm Pharm Sci 2014;6:449–55
   Google Scholar
• Gao L, Zhang D, Chen M, et al. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm 2007;33:1332–9
   PubMed Web of Science ®Google Scholar
• Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm 2011;79:635–51
   PubMedGoogle Scholar
• Yadav KS, Sawant KK. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech 2010;11:1456–65
   PubMed Web of Science ®Google Scholar
• Jawahar N, Meyyanathan SN, Senthil V, et al. Studies on physico-chemical and pharmacokinetic properties of olanzapine through nanosuspension. J Pharm Sci Res 2013;5:196–202
   Google Scholar
• Sahu BP, Das MK. Formulation, optimization, and in vitro/in vivo evaluation of furosemide nanosuspension for enhancement of its oral bioavailability. J Nanopart Res 2014;2360:1–16
   Google Scholar
• Pardeike J, Strohmeier DM, Schrodl N, et al. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines. Int J Pharm 2011;420:93–100
   PubMed Web of Science ®Google Scholar
• Patel GV, Patel VB, Pathak A, Rajput SJ. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Drug Dev Ind Pharm 2014;40:80–91
   PubMed Web of Science ®Google Scholar
• Chavhan S, Joshi G, Petkar K, Sawant K. Enhanced bioavailability and hypolipidemic activity of Simvastatin formulations by particle size engineering: physicochemical aspects and in vivo investigations. Biochem Eng J 2013;79:221–9
   Web of Science ®Google Scholar
• Yadav SK, Mishra S, Mishra B. Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation. AAPS PharmSciTech 2012;13:1031–44
   PubMed Web of Science ®Google Scholar
• Salazar J, Ghanem A, Muller RH, Moschwitzer JP. Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Eur J Pharm Biopharm 2012;81:82–90
   PubMed Web of Science ®Google Scholar
• Raju A, Reddy AJ, Satheesh J, Jithan AV. Preparation and characterisation of nevirapine oral nanosuspensions. Indian J Pharm Sci 2014;76:62–71
   PubMed Web of Science ®Google Scholar
• Jacobs C, Kayser O, Muller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm 2000;196:161–4
   PubMed Web of Science ®Google Scholar
• Gora S, Mustafa G, Sahni JK, et al. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodynamic study. Drug Deliv 2014;1–11
   Web of Science ®Google Scholar
• Langguth P, Hanafy A, Frenzel D, et al. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm 2005;31:319–29
   PubMed Web of Science ®Google Scholar